147 related articles for article (PubMed ID: 17257714)
21. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
23. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
24. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
Perdiguero B; Gómez CE; Nájera JL; Sorzano CO; Delaloye J; González-Sanz R; Jiménez V; Roger T; Calandra T; Pantaleo G; Esteban M
PLoS One; 2012; 7(10):e48524. PubMed ID: 23119046
[TBL] [Abstract][Full Text] [Related]
25. Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101(+) patients protected mice against chimaeric ecotropic HIV-1 challenge.
Roshorm Y; Hong JP; Kobayashi N; McMichael AJ; Volsky DJ; Potash MJ; Takiguchi M; Hanke T
Eur J Immunol; 2009 Jul; 39(7):1831-40. PubMed ID: 19585509
[TBL] [Abstract][Full Text] [Related]
26. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
Hanke T; Barnfield C; Wee EG; Ågren L; Samuel RV; Larke N; Liljeström P
J Gen Virol; 2003 Feb; 84(Pt 2):361-368. PubMed ID: 12560568
[TBL] [Abstract][Full Text] [Related]
27. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.
Ourmanov I; Brown CR; Moss B; Carroll M; Wyatt L; Pletneva L; Goldstein S; Venzon D; Hirsch VM
J Virol; 2000 Mar; 74(6):2740-51. PubMed ID: 10684290
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
[TBL] [Abstract][Full Text] [Related]
29. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice.
Hanke T; McMichael AJ; Dennis MJ; Sharpe SA; Powell LA; McLoughlin L; Crome SJ
Vaccine; 2005 Feb; 23(12):1507-14. PubMed ID: 15670887
[TBL] [Abstract][Full Text] [Related]
30. Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
Im EJ; Nkolola JP; di Gleria K; McMichael AJ; Hanke T
Eur J Immunol; 2006 Oct; 36(10):2574-84. PubMed ID: 17013988
[TBL] [Abstract][Full Text] [Related]
31. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.
Rosario M; Hopkins R; Fulkerson J; Borthwick N; Quigley MF; Joseph J; Douek DC; Greenaway HY; Venturi V; Gostick E; Price DA; Both GW; Sadoff JC; Hanke T
J Virol; 2010 Jun; 84(12):5898-908. PubMed ID: 20375158
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.
Greenough TC; Cunningham CK; Muresan P; McManus M; Persaud D; Fenton T; Barker P; Gaur A; Panicali D; Sullivan JL; Luzuriaga K;
Vaccine; 2008 Dec; 26(52):6883-93. PubMed ID: 18940219
[TBL] [Abstract][Full Text] [Related]
33. HIV-1-specific CD4+ T-cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia.
Koeppe JR; Campbell TB; Rapaport EL; Wilson CC
J Acquir Immune Defic Syndr; 2006 Feb; 41(2):140-8. PubMed ID: 16394844
[TBL] [Abstract][Full Text] [Related]
34. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
36. Preclinical development of BCG.HIVA
Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
[TBL] [Abstract][Full Text] [Related]
37. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
38. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
[TBL] [Abstract][Full Text] [Related]
39. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
[TBL] [Abstract][Full Text] [Related]
40. DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.
Gorse GJ; Newman MJ; deCamp A; Hay CM; De Rosa SC; Noonan E; Livingston BD; Fuchs JD; Kalams SA; Cassis-Ghavami FL;
Clin Vaccine Immunol; 2012 May; 19(5):649-58. PubMed ID: 22398243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
